Recently, the Department of Medical Insurance Pricing and Procurement and the Guidance Center for Medical Insurance Pricing and Procurement of the National Healthcare Security Administration jointly issued the "Guidelines for the Establishment of Medical Service Pricing Items for Laboratory Tests (Draft for Re-comment)," expanding the number of items from 573 to 628, comprehensively promoting the standardization of laboratory test fees. The changes in the field of coagulation testing are particularly significant, with a comprehensive upgrade in project structure, professional ranking, and classification logic. This marks a formal shift in coagulation function testing from "basic screening" to the construction of a "complete system," providing standardized and regulated guidance for precision clinical diagnosis and treatment.

This systematic expansion of coagulation testing items is not simply an increase in quantity, but a profound upgrade driven by clinical needs:
1- Diagnosis shifts from "qualitative" to "source-based": New items such as corrective tests and heparin monitoring allow clinicians not only to detect "coagulation abnormalities" but also to accurately pinpoint the abnormal processes, providing a basis for etiological diagnosis and medication adjustment.

2. Treatment Shifts from "Experience-Based" to "Evidence-Based": The refinement of testing methods, such as anticoagulant monitoring and fibrinolytic system biomarkers, provides standardized tools for evaluating the efficacy and managing the risks of antithrombotic and thrombolytic therapies.

3. Disease Management Shifts from "Single-Function" to "Comprehensive": From basic screening and etiological classification to efficacy monitoring and prognostic assessment, a complete testing system provides closed-loop support for the full-cycle management of thrombotic and hemorrhagic diseases.

The release of the new "Guidelines for the Establishment of Pricing Items for Laboratory Medical Services" points the way for the standardized and regulated development of coagulation testing.

SUCCEEDER will continue to closely follow policy guidance, assisting medical institutions in building complete thrombosis and hemostasis testing platforms, jointly promoting coagulation testing from "basic screening" to a new era of "precision diagnosis and treatment," safeguarding the lives and health of more patients.